Structure of PINK1 in complex with its substrate ubiquitin

Nature

Volumn 552, Issue , 2017, Pages 51-56

  Schubert, Alexander F ^a   Gladkova, Christina ^a   Pardon, Els ^b,c   Wagstaff, Jane L ^a   Freund, Stefan M V ^a   Steyaert, Jan ^b,c   Maslen, Sarah L ^a   Komander, David ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

NANOBODY; PROTEIN KINASE; PROTEIN KINASE PINK1; SERINE; UBIQUITIN; UNCLASSIFIED DRUG; PTEN-INDUCED PUTATIVE KINASE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

CHEMICAL BINDING; CRYSTAL STRUCTURE; GENE EXPRESSION; JUVENILE; MOLECULAR ANALYSIS; MUTATION; PROTEIN;

ARTICLE; AUTOPHOSPHORYLATION; CARBOXY TERMINAL SEQUENCE; CRYSTAL STRUCTURE; NONHUMAN; PEDICULUS HUMANUS CORPORIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; ANIMAL; BINDING SITE; CHEMISTRY; ENZYMOLOGY; GENETICS; IMMUNOLOGY; METABOLISM; MITOPHAGY; MOLECULAR MODEL; MUTATION; PEDICULUS; PHOSPHORYLATION; X RAY CRYSTALLOGRAPHY;

PEDICULUS HUMANUS CORPORIS;

ANIMALS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; MITOCHONDRIAL DEGRADATION; MODELS, MOLECULAR; MUTATION; PEDICULUS; PHOSPHORYLATION; PROTEIN KINASES; SINGLE-CHAIN ANTIBODIES; UBIQUITIN;

EID: 85041123859     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature24645     Document Type: Article

References (62)

1. Hoehn, M. M. & Yahr, M. D. Parkinsonism: onset, progression and mortality. Neurology 17, 427-442 (1967).
2. Corti, O., Lesage, S. & Brice, A. What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol. Rev. 91, 1161-1218 (2011).
3. Valente, E. M. et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158-1160 (2004).
4. Clark, I. E. et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441, 1162-1166 (2006).
5. Park, J. et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441, 1157-1161 (2006).
6. Yang, Y. et al. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci USA 103, 10793-10798 (2006).
7. Hewitt, V. L. & Whitworth, A. J. Mechanisms of Parkinson's Disease: Lessons from Drosophila. Curr. Top. Dev. Biol. 121, 173-200 (2017).
8. Poole, A. C. et al. The PINK1/Parkin pathway regulates mitochondrial morphology. Proc Natl Acad Sci USA 105, 1638-1643 (2008).
9. Pickrell, A. M. & Youle, R. J. The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson's Disease. Neuron 85, 257-273 (2015).
10. Bingol, B. & Sheng, M. Mechanisms of mitophagy: PINK1, Parkin, USP30 and beyond. Free Radic Biol Med 100, 210-222 (2016).
11. Kazlauskaite, A. & Muqit, M. M. K. PINK1 and Parkin - mitochondrial interplay between phosphorylation and ubiquitylation in Parkinson's disease. FEBS J 282, 215-223 (2015).
12. Narendra, D. P. et al. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol 8, e1000298 (2010).
13. Okatsu, K. et al. PINK1 autophosphorylation upon membrane potential dissipation is essential for Parkin recruitment to damaged mitochondria. Nature Communications 3, 1016 (2012).
14. Okatsu, K. et al. A dimeric PINK1-containing complex on depolarized mitochondria stimulates Parkin recruitment. J Biol Chem 288, 36372-36384 (2013).
15. Aerts, L., Craessaerts, K., De Strooper, B. & Morais, V. A. PINK1 kinase catalytic activity is regulated by phosphorylation on serines 228 and 402. J Biol Chem 290, 2798-2811 (2015).
16. Kondapalli, C. et al. PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65. Open Biology 2, 120080 (2012).
17. Koyano, F. et al. Ubiquitin is phosphorylated by PINK1 to activate parkin. Nature 510, 162-166 (2014).
18. Kane, L. A. et al. PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. J Cell Biol 205, 143-153 (2014).
19. Kazlauskaite, A. et al. Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65. Biochem J 460, 127-139 (2014).
20. Wauer, T. et al. Ubiquitin Ser65 phosphorylation afects ubiquitin structure, chain assembly and hydrolysis. EMBO J 34, 307-325 (2015).
21. Ordureau, A. et al. Quantitative Proteomics Reveal a Feedforward Mechanism for Mitochondrial PARKIN Translocation and Ubiquitin Chain Synthesis. Mol Cell 56, 360-375 (2014).
22. Wauer, T., Simicek, M., Schubert, A. F. & Komander, D. Mechanism of phospho-ubiquitin-induced PARKIN activation. Nature 524, 370-374 (2015).
23. Sauvé, V. et al. A Ubl/ubiquitin switch in the activation of Parkin. EMBO J 34, 2492-2505 (2015).
24. Kumar, A. et al. Disruption of the autoinhibited state primes the E3 ligase parkin for activation and catalysis. EMBO J 34, 2506-2521 (2015).
25. Kazlauskaite, A. et al. Binding to serine 65-phosphorylated ubiquitin primes Parkin for optimal PINK1-dependent phosphorylation and activation. EMBO Rep 16, 939-954 (2015).
26. Sarraf, S. A. et al. Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization. Nature 496, 372-376 (2013).
27. Lazarou, M. et al. The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy. Nature 524, 309-314 (2015).
28. Heo, J.-M., Ordureau, A., Paulo, J. A., Rinehart, J. & Harper, J. W. The PINK1-PARKIN Mitochondrial Ubiquitylation Pathway Drives a Program of OPTN/NDP52 Recruitment and TBK1 Activation to Promote Mitophagy. Mol Cell 60, 7-20 (2015).
29. Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912-1934 (2002).
30. Woodroof, H. I. et al. Discovery of catalytically active orthologues of the Parkinson's disease kinase PINK1: analysis of substrate specifcity and impact of mutations. Open Biology 1, 110012 (2011).
31. Gladkova, C. et al. An 'invisible' ubiquitin conformation is required for efcient phosphorylation by PINK1. EMBO J (2017). doi:10.15252/embj.201797876
32. Pleiner, T. et al. Nanobodies: site-specifc labeling for super-resolution imaging, rapid epitope-mapping and native protein complex isolation. eLife 4, e11349 (2015).
33. Knighton, D. R. et al. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253, 407-414 (1991).
34. Lowe, E. D. et al. The crystal structure of a phosphorylase kinase peptide substrate complex: kinase substrate recognition. EMBO J 16, 6646-6658 (1997).
35. Johnson, L. N., Noble, M. E. & Owen, D. J. Active and inactive protein kinases: structural basis for regulation. Cell 85, 149-158 (1996).
36. Taylor, S. S. & Kornev, A. P. Protein kinases: evolution of dynamic regulatory proteins. Trends Biochem Sci 36, 65-77 (2011).
37. Sim, C. H. et al. C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. Hum Mol Genet 15, 3251-3262 (2006).
38. Gersch, M. et al. Mechanism and regulation of the Lys6-selective deubiquitinase USP30. Nat Struct Mol Biol 510, 370 (2017).
39. Aerts, L., De Strooper, B. & Morais, V. A. PINK1 activation-turning on a promiscuous kinase. Biochem Soc Trans 43, 280-286 (2015).
40. Matenia, D., Hempp, C., Timm, T., Eikhof, A. & Mandelkow, E.-M. Microtubule afnity-regulating kinase 2 (MARK2) turns on phosphatase and tensin homolog (PTEN)-induced kinase 1 (PINK1) at Thr-313, a mutation site in Parkinson disease: efects on mitochondrial transport. J Biol Chem 287, 8174-8186 (2012).
41. Dar, A. C., Dever, T. E. & Sicheri, F. Higher-order substrate recognition of eIF2alpha by the RNA-dependent protein kinase PKR. Cell 122, 887-900 (2005).
42. Kumar, A. et al. Structure of PINK1 and mechanisms of Parkinson's disease associated mutations. eLife 1-29 (2017). doi:https://doi.org/10.1101/189027
43. Hertz, N. T. et al. A neo-substrate that amplifes catalytic activity of parkinson'sdisease-related kinase PINK1. Cell 154, 737-747 (2013).
44. Berrow, N. S. et al. A versatile ligation-independent cloning method suitable for high-throughput expression screening applications. Nucleic Acids Res 35, e45 (2007).
45. Pardon, E. et al. A general protocol for the generation of Nanobodies for structural biology. Nat Protoc 9, 674-693 (2014).
46. Waterman, D. G. et al. Difraction-geometry refnement in the DIALS framework. Acta Crystallogr D Struct Biol 72, 558-575 (2016).
47. McCoy, A. J. et al. Phaser crystallographic software. J Appl Crystallogr 40, 658-674 (2007).
48. Jiang, X. et al. Crystal structure of a LacY-nanobody complex in a periplasmicopen conformation. Proceedings of the National Academy of Sciences 113, 12420-12425 (2016).
49. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66, 486-501 (2010).
50. Adams, P. D. et al. The Phenix software for automated determination of macromolecular structures. Methods 55, 94-106 (2011).
51. Silva, J. C. et al. Quantitative proteomic analysis by accurate mass retention time pairs. Anal Chem 77, 2187-2200 (2005).
52. Edgar, R. C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 32, 1792-1797 (2004).
53. Dong, X. et al. Ubiquitin S65 phosphorylation engenders a pH-sensitive conformational switch. Proceedings of the National Academy of Sciences 114, 6770-6775 (2017).
54. Vallurupalli, P., Bouvignies, G. & Kay, L. E. Studying 'invisible' excited protein states in slow exchange with a major state conformation. J Am Chem Soc 134, 8148-8161 (2012).
55. Holm, L. & Rosenström, P. Dali server: conservation mapping in 3D. Nucleic Acids Res 38, W545-9 (2010).
56. Wen, Y. et al. Structural evaluation of a nanobody targeting complement receptor Vsig4 and its cross reactivity. Immunobiology 222, 807-813 (2017).
57. Vijay-Kumar, S., Bugg, C. E. & Cook, W. J. Structure of ubiquitin refned at 1.8 A resolution. J Mol Biol 194, 531-544 (1987).
58. Hamill, S., Lou, H. J., Turk, B. E. & Boggon, T. J. Structural Basis for Noncanonical Substrate Recognition of Coflin/ADF Proteins by LIM Kinases. Mol Cell 62, 397-408 (2016).
59. Yokoyama, T., Kosaka, Y. & Mizuguchi, M. Structural Insight into the Interactions between Death-Associated Protein Kinase 1 and Natural Flavonoids. J. Med. Chem. 58, 7400-7408 (2015).
60. Wong, Y. L. et al. Reversible centriole depletion with an inhibitor of Polo-like kinase 4. Science 348, 1155-1160 (2015).
61. Pei, J., Kim, B.-H. & Grishin, N. V. PROMALS3D: a tool for multiple protein sequence and structure alignments. Nucleic Acids Res 36, 2295-2300 (2008).
62. Aguirre, J. D., Dunkerley, K. M., Mercier, P. & Shaw, G. S. Structure of phosphorylated UBL domain and insights into PINK1-orchestrated parkin activation. Proceedings of the National Academy of Sciences 114, 298-303 (2017).